- Report
- April 2024
- 132 Pages
Global
From €900EUR$950USD£760GBP
- Report
- April 2024
- 132 Pages
Global
From €900EUR$950USD£760GBP
- Book
- June 2014
- 600 Pages
- Book
- September 2009
- 600 Pages
- Report
- November 2021
- 270 Pages
Global
From €2369EUR$2,500USD£1,999GBP
- Book
- October 2018
- 488 Pages
The Companion Diagnostics market is a subset of the biotechnology industry that focuses on the development and commercialization of diagnostic tests that are used to identify patients who are likely to benefit from a particular therapeutic. These tests are used to identify the presence of a specific biomarker or genetic mutation that is associated with a particular therapeutic. The Companion Diagnostics market is driven by the increasing demand for personalized medicine, which is tailored to the individual patient's genetic makeup. This has led to the development of more sophisticated tests that can detect a wider range of biomarkers and mutations.
The Companion Diagnostics market is highly competitive, with a number of companies offering a range of tests. Examples of companies in the market include Roche Diagnostics, Abbott Laboratories, Qiagen, Illumina, and Thermo Fisher Scientific. Show Less Read more